

Bayer awards the Cholangiocarcinoma Foundation Funding for Proposal to Help Patients

The competitive grant from Bayer will help CCF expand outreach to community oncologists and patients to emphasize the importance of genetic testing.

SALT LAKE CITY, UT, USA, June 14, 2018 /EINPresswire.com/ -- The Cholangiocarcinoma Foundation (CCF), a nonprofit organization funding novel research for bile duct cancer, was recently awarded top prize at the Bayer 6th Annual Patient Advocacy Summit. This prestigious award will support CCF's goal to educate patients about the importance of genetic testing while encouraging patient participation in clinical trials.



“We are incredibly grateful for this support which will assist us to work with our partner organizations to expand outreach and education to community oncologists and their patients in innovative ways,” Stacie Lindsey, CCF Founder and President stated. “A large majority of patients are not seen at a major cancer center where they have access to the most current research available. This is a cancer where the science is moving quickly and patients should be aware that there are new treatment options emerging.”

“

The Patient Advocacy Summit focuses on the many ways in which the patient voice can be incorporated in all of Bayer's corporate objectives to make a difference in patients' lives”

Gissoo DeCotiis, Head of Advocacy, Bayer Oncology

CCF was one of twenty-two advocacy organizations asked to submit a proposal for funding. Three patient organizations were then chosen to present their proposals in the “Shark Tank” like competition. CCF won first prize while the two other

organizations were both awarded second place.

[CCF has partnered with](#) several organizations on the proposal including, Komodo Health, DMD Communications, D2Creative, Ein Communications, Foundation Medicine, and Perthera. According to Donna Mayer, CCF Executive Director, “without the contribution of our partner organizations we would not have been successful in receiving this grant”.

About Cholangiocarcinoma

Cholangiocarcinoma, a highly lethal cancer with poor prognosis, arises from the bile ducts in the liver. It is often diagnosed at advanced stages when treatment is only minimally effective, emphasizing the

imminent need for novel therapies. There are no effective strategies for prevention, early diagnosis or long-term treatment, indicating a significant unmet medical need.

Although considered rare, with 12,000 cases a year being diagnosed in the US, cholangiocarcinoma is the second most common primary liver cancer in the world. Both incidence and mortality are increasing thus research into this deadly disease is urgently needed.

About the Cholangiocarcinoma Foundation

Founded in 2006, the Cholangiocarcinoma Foundation is a global 501(c) (3) non-profit organization whose mission is to find a cure and improve the quality of life for those affected by bile duct cancer. As a rare and lethal disease, cholangiocarcinoma lacks attention and sufficient resources. There is a vast, unmet need for education about cholangiocarcinoma across the entire disease spectrum - from bench to bedside. For that reason, the Cholangiocarcinoma Foundation continues its efforts to raise awareness of all stakeholders in the cholangiocarcinoma community through advocacy, education, collaboration and research. More information is available at cholangiocarcinoma.org.

Jordan Giles

Cholangiocarcinoma Foundation

888-396-6731x10

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2018 IPD Group, Inc. All Right Reserved.